New Lipid Lowering Therapies for Cardiovascular and Metabolic Diseases: Lessons from the Past and Future Challenges
This book illustrates some of the most recent research efforts that have been made in lowering plasma cholesterol levels in patients with CVD. Selected articles aimed to illuminate advances and urgent challenges in the management of CVD, including disease management using statin-combined therapeutic...
保存先:
| 第一著者: | |
|---|---|
| フォーマット: | Online |
| 言語: | 英語 |
| 出版事項: |
MDPI - Multidisciplinary Digital Publishing Institute
2021
|
| 主題: | |
| オンライン･アクセス: | 42589 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|
| _version_ | 1869531368346615808 |
|---|---|
| author | Bakillah, Ahmed |
| author_browse | Bakillah, Ahmed |
| author_facet | Bakillah, Ahmed |
| author_sort | Bakillah, Ahmed |
| collection | Directory of Open Access Books |
| description | This book illustrates some of the most recent research efforts that have been made in lowering plasma cholesterol levels in patients with CVD. Selected articles aimed to illuminate advances and urgent challenges in the management of CVD, including disease management using statin-combined therapeutic strategies. |
| format | Online |
| id | doab-20.500.12854ir-54599 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2021 |
| publishDateRange | 2021 |
| publishDateSort | 2021 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-545992024-04-05T12:33:42Z New Lipid Lowering Therapies for Cardiovascular and Metabolic Diseases: Lessons from the Past and Future Challenges Bakillah, Ahmed QH301-705.5 Q1-390 apolipoprotein lipids risk stratification proprotein convertase subtilisin-kexin type 9 (PCSK9) vaspin sphingolipids PCSK9 ceramides atrial fibrillation circular RNA STEMI cholesterol lipoproteins cardiovascular disease (CVD) coronary artery bypass grafting atherosclerosis statin LDL subfractions acute kidney injury dyslipidemia gene expression NSTEMI NAFLD hyperlipidemia nonstatin cholesteryl ester transfer protein low-density lipoprotein cholesterol anacetrapib HDL acute coronary syndrome miRNA cardiovascular risk pleiotropic actions genetic ABCA1 sdLDL cardiovascular disease proprotein convertase subtilisin/kexin type 9 inclisiran reverse cholesterol transport sterol small interfering RNA (siRNA) RNA-binding proteins cardiovascular diseases NASH low-density lipoprotein-cholesterol (LDL-C) stroke nutrigenetics type 2 diabetes statins sphingomyelin hepatic fibrosis diabetes thema EDItEUR::P Mathematics and Science::PS Biology, life sciences This book illustrates some of the most recent research efforts that have been made in lowering plasma cholesterol levels in patients with CVD. Selected articles aimed to illuminate advances and urgent challenges in the management of CVD, including disease management using statin-combined therapeutic strategies. 2021-02-11T20:55:44Z 2021-02-11T20:55:44Z 2019-12-09 11:49:16 2019 book 42589 9783039216772 9783039216765 https://directory.doabooks.org/handle/20.500.12854/54599 eng application/octet-stream Attribution-NonCommercial-NoDerivatives 4.0 International https://mdpi.com/books/pdfview/book/1720 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-03921-677-2 10.3390/books978-3-03921-677-2 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783039216772 9783039216765 116 open access |
| spellingShingle | QH301-705.5 Q1-390 apolipoprotein lipids risk stratification proprotein convertase subtilisin-kexin type 9 (PCSK9) vaspin sphingolipids PCSK9 ceramides atrial fibrillation circular RNA STEMI cholesterol lipoproteins cardiovascular disease (CVD) coronary artery bypass grafting atherosclerosis statin LDL subfractions acute kidney injury dyslipidemia gene expression NSTEMI NAFLD hyperlipidemia nonstatin cholesteryl ester transfer protein low-density lipoprotein cholesterol anacetrapib HDL acute coronary syndrome miRNA cardiovascular risk pleiotropic actions genetic ABCA1 sdLDL cardiovascular disease proprotein convertase subtilisin/kexin type 9 inclisiran reverse cholesterol transport sterol small interfering RNA (siRNA) RNA-binding proteins cardiovascular diseases NASH low-density lipoprotein-cholesterol (LDL-C) stroke nutrigenetics type 2 diabetes statins sphingomyelin hepatic fibrosis diabetes thema EDItEUR::P Mathematics and Science::PS Biology, life sciences Bakillah, Ahmed New Lipid Lowering Therapies for Cardiovascular and Metabolic Diseases: Lessons from the Past and Future Challenges |
| title | New Lipid Lowering Therapies for Cardiovascular and Metabolic Diseases: Lessons from the Past and Future Challenges |
| title_full | New Lipid Lowering Therapies for Cardiovascular and Metabolic Diseases: Lessons from the Past and Future Challenges |
| title_fullStr | New Lipid Lowering Therapies for Cardiovascular and Metabolic Diseases: Lessons from the Past and Future Challenges |
| title_full_unstemmed | New Lipid Lowering Therapies for Cardiovascular and Metabolic Diseases: Lessons from the Past and Future Challenges |
| title_short | New Lipid Lowering Therapies for Cardiovascular and Metabolic Diseases: Lessons from the Past and Future Challenges |
| title_sort | new lipid lowering therapies for cardiovascular and metabolic diseases lessons from the past and future challenges |
| topic | QH301-705.5 Q1-390 apolipoprotein lipids risk stratification proprotein convertase subtilisin-kexin type 9 (PCSK9) vaspin sphingolipids PCSK9 ceramides atrial fibrillation circular RNA STEMI cholesterol lipoproteins cardiovascular disease (CVD) coronary artery bypass grafting atherosclerosis statin LDL subfractions acute kidney injury dyslipidemia gene expression NSTEMI NAFLD hyperlipidemia nonstatin cholesteryl ester transfer protein low-density lipoprotein cholesterol anacetrapib HDL acute coronary syndrome miRNA cardiovascular risk pleiotropic actions genetic ABCA1 sdLDL cardiovascular disease proprotein convertase subtilisin/kexin type 9 inclisiran reverse cholesterol transport sterol small interfering RNA (siRNA) RNA-binding proteins cardiovascular diseases NASH low-density lipoprotein-cholesterol (LDL-C) stroke nutrigenetics type 2 diabetes statins sphingomyelin hepatic fibrosis diabetes thema EDItEUR::P Mathematics and Science::PS Biology, life sciences |
| topic_facet | QH301-705.5 Q1-390 apolipoprotein lipids risk stratification proprotein convertase subtilisin-kexin type 9 (PCSK9) vaspin sphingolipids PCSK9 ceramides atrial fibrillation circular RNA STEMI cholesterol lipoproteins cardiovascular disease (CVD) coronary artery bypass grafting atherosclerosis statin LDL subfractions acute kidney injury dyslipidemia gene expression NSTEMI NAFLD hyperlipidemia nonstatin cholesteryl ester transfer protein low-density lipoprotein cholesterol anacetrapib HDL acute coronary syndrome miRNA cardiovascular risk pleiotropic actions genetic ABCA1 sdLDL cardiovascular disease proprotein convertase subtilisin/kexin type 9 inclisiran reverse cholesterol transport sterol small interfering RNA (siRNA) RNA-binding proteins cardiovascular diseases NASH low-density lipoprotein-cholesterol (LDL-C) stroke nutrigenetics type 2 diabetes statins sphingomyelin hepatic fibrosis diabetes thema EDItEUR::P Mathematics and Science::PS Biology, life sciences |
| url | 42589 |
| work_keys_str_mv | AT bakillahahmed newlipidloweringtherapiesforcardiovascularandmetabolicdiseaseslessonsfromthepastandfuturechallenges |